// App-Quantinova.ai

271 : Influence of autophagy modulation on synergistic interactions of lapatinib and mTOR targeted agents in HER2-amplified lapatinib resistant breast cancer models in vitro and in vivo

Researchers

Presenter

  • Wieslawa H. Dragowska

Principal Investigators

  • Sherry A. Weppler

  • William Wei Chu

  • Norman S. Chow

  • Jenna S. Rawji

  • Ashleen S. Prasad

  • Karen A. Gelmon

  • Sharon M. Gorski

  • Marcel B. Bally

Medical Centers

  • Experimental Therapeutics, BC Cancer Agency Precision NanoSystems, Vancouver, British Columbia, Canada

  • Medical Oncology, BC Cancer Agency Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

  • Michael Smith Genome Sciences Centre, BC Cancer Agency Department of Molecular Biology and Biochemistry, Simon Fraser University, Vancouver and Burnaby, British Columbia, Canada

  • Experimental Therapeutics, BC Cancer Agency Faculty of Pharmaceutical Sciences, Department of Pathology and Laboratory Medicine, University of British Columbia Centre for Drug Research and Development, Vancouver, British Columbia, Canada.

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Beclin-1

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Human epidermal growth factor receptor 2

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • Hydroxychloroquine

  • KU-0063794

  • Lapatinib

  • AZD-2014

Outcome

  • N/A

Study Design

  • Adaptive

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved